je.st
news
Tag: breast
NIST develops measurement standard for breast cancer MRI.
2016-03-24 13:31:09| Industrial Newsroom - All News for Today
Researchers at NIST have developed the first widely useful standard for magnetic resonance imaging of the breast. NIST phantom will help standardize MRIs of breast tissue and ensure quality control in comparing images within and between medical research studies. Phantom mimics response of human tissue to help test performance of medical imaging systems. It supports quantitative MRI, which is increasingly used for breast cancer diagnosis, staging, and treatment monitoring.
Tags: standard
cancer
measurement
breast
FDA clears expanded use of Pfizer's breast cancer med IBRANCE
2016-02-20 09:04:41| Biotech - Topix.net
The FDA approves Pfizer's supplement New Drug Application for IBRANCE . It is now cleared for the treatment of hormone receptor-positive , human epidermal growth factor receptor 2-negative advanced/metastatic breast cancer in combination with fulvestrant [AstraZeneca's FASLODEX ] in women with disease progression following endocrine therapy.
Tags: med
expanded
cancer
breast
Around the state at 27km/h to beat breast cancer
2016-01-05 13:15:09| Real Estate - Topix.net
It was a 2am brainwave that prompted Hugh Bateman to buy a tractor from a Sydney auction. A lick of pink paint back in his hometown of Mudgee and the 64-year-old real estate agent was ready for the 27km/h road trip of a lifetime.
Tags: state
cancer
beat
breast
The racket behind Pfizer's new $9,850 breast cancer drug
2015-12-12 11:33:08| Biotech - Topix.net
Laura Robison of Minneapolis used crowdfunding to help pay for Ibance, a breast cancer treatment drug that hit the market less than a year ago. Robison's disease is Stage 3. She's seeking donations to cover her medical expenses, which add up fast considering the monthly cost for Ibance is almost $10,000.
Tags: drug
cancer
breast
racket
Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer ...
2015-12-09 01:44:52| Biotech - Topix.net
Oncothyreon Inc. , a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced updated data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of HER2-positive metastatic breast cancer. The data will be the subject of two presentations at the San Antonio Breast Cancer Symposium being held December 8-12, 2015 in San Antonio, TX.
Tags: data
cancer
breast
announces
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »